To address the World Health Organization (WHO) target set to cut malaria cases and deaths by at least 90%, GSK has scientists carrying out innovative research focused on the very earliest stages of discovery. Its researchers get to see almost all of the medicines that are in development across the global malaria community because its technology gives researchers a chance to determine their compound’s potential to kill the malaria parasite quickly.
The company also shares its own compounds and data with scientists to help advance the pace of progress in malaria research. More than 2 million compounds in its chemical library have been screened for activity against the malaria parasite.
Links: